These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 24803420)
1. Comment on "Quality by design approach for understanding the critical quality attributes of cyclosporine ophthalmic emulsion". Gore A; Attar M; Pujara C; Neervannan S Mol Pharm; 2014 Jul; 11(7):2490-2. PubMed ID: 24803420 [No Abstract] [Full Text] [Related]
2. Quality by design approach for understanding the critical quality attributes of cyclosporine ophthalmic emulsion. Rahman Z; Xu X; Katragadda U; Krishnaiah YS; Yu L; Khan MA Mol Pharm; 2014 Mar; 11(3):787-99. PubMed ID: 24423028 [TBL] [Abstract][Full Text] [Related]
3. Quality by design: understanding the formulation variables of a cyclosporine A self-nanoemulsified drug delivery systems by Box-Behnken design and desirability function. Zidan AS; Sammour OA; Hammad MA; Megrab NA; Habib MJ; Khan MA Int J Pharm; 2007 Mar; 332(1-2):55-63. PubMed ID: 17169518 [TBL] [Abstract][Full Text] [Related]
4. Asymmetric flow field flow fractionation for the characterization of globule size distribution in complex formulations: A cyclosporine ophthalmic emulsion case. Qu H; Wang J; Wu Y; Zheng J; Krishnaiah YSR; Absar M; Choi S; Ashraf M; Cruz CN; Xu X Int J Pharm; 2018 Mar; 538(1-2):215-222. PubMed ID: 29341918 [TBL] [Abstract][Full Text] [Related]
5. Cyclosporine A delivery to the eye: A comprehensive review of academic and industrial efforts. Lallemand F; Schmitt M; Bourges JL; Gurny R; Benita S; Garrigue JS Eur J Pharm Biopharm; 2017 Aug; 117():14-28. PubMed ID: 28315447 [TBL] [Abstract][Full Text] [Related]
6. Comparative study of cyclosporine A liposomes and emulsions for ophthalmic drug delivery: Process optimization through response surface methodology (RSM) and biocompatibility evaluation. Li Y; Guan Q; Xu J; Zhang H; Liu S; Ding Z; Wang Q; Wang Z; Liu M; Zhao Y Colloids Surf B Biointerfaces; 2023 May; 225():113267. PubMed ID: 36940502 [TBL] [Abstract][Full Text] [Related]
7. Analytical considerations for measuring the globule size distribution of cyclosporine ophthalmic emulsions. Petrochenko PE; Pavurala N; Wu Y; Yee Wong S; Parhiz H; Chen K; Patil SM; Qu H; Buoniconti P; Muhammad A; Choi S; Kozak D; Ashraf M; Cruz CN; Zheng J; Xu X Int J Pharm; 2018 Oct; 550(1-2):229-239. PubMed ID: 30125649 [TBL] [Abstract][Full Text] [Related]
8. Stability of an ophthalmic micellar formulation of cyclosporine A in unopened multidose eyedroppers and in simulated use conditions. Chennell P; Delaborde L; Wasiak M; Jouannet M; Feschet-Chassot E; Chiambaretta F; Sautou V Eur J Pharm Sci; 2017 Mar; 100():230-237. PubMed ID: 28131754 [TBL] [Abstract][Full Text] [Related]
19. Unusual corneal deposit after the topical use of cyclosporine as eyedrops. Kachi S; Hirano K; Takesue Y; Miura M Am J Ophthalmol; 2000 Nov; 130(5):667-9. PubMed ID: 11078849 [TBL] [Abstract][Full Text] [Related]
20. Biowaiver extension potential and IVIVC for BCS Class II drugs by formulation design: Case study for cyclosporine self-microemulsifying formulation. Yang SG Arch Pharm Res; 2010 Nov; 33(11):1835-42. PubMed ID: 21116787 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]